Randomised controlled trial of oxygen therapy and high-flow nasal therapy in African children with pneumonia
Autor: | Kathryn Maitland, Florence Alaroker, Mainga Hamaluba, Charles Engoru, Abner Tagoola, H Mnjella, David A Harrison, John F. Fraser, Karen Thomas, Bandika, Sarah Kiguli, Thomas N. Williams, Peter Olupot-Olupot, William Okiror, E Oguda, Kathy Rowan, Robert O. Opoka, Ayub Mpoya, Eva Nabawanuka, Denis Aromut, Margeret Nakuya |
---|---|
Přispěvatelé: | group, COAST trial, Medical Research Council (MRC), DFID/MRC/Wellcome Trust, European and Developing Countries Clinical Trials Partnership, Wellcome Trust |
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
Original medicine.medical_treatment INFANTS Critical Care and Intensive Care Medicine 1117 Public Health and Health Services law.invention 03 medical and health sciences 0302 clinical medicine Critical Care Medicine Randomized controlled trial High-flow nasal therapy law General & Internal Medicine Oxygen therapy Anesthesiology Internal medicine medicine Clinical endpoint Humans Child Hypoxia Science & Technology business.industry MORTALITY AIR Mortality rate Uncertainty Oxygen Inhalation Therapy 1103 Clinical Sciences 030208 emergency & critical care medicine Pneumonia HYPOXEMIA Odds ratio COAST trial group medicine.disease Kenya Emergency & Critical Care Medicine respiratory tract diseases Oxygen Clinical trial 030228 respiratory system African children business Life Sciences & Biomedicine |
Zdroj: | Intensive Care Medicine |
ISSN: | 1432-1238 0342-4642 |
Popis: | Purpose The life-saving role of oxygen therapy in African children with severe pneumonia is not yet established. Methods The open-label fractional-factorial COAST trial randomised eligible Ugandan and Kenyan children aged > 28 days with severe pneumonia and severe hypoxaemia stratum (SpO2 3 h receipt of oxygen were excluded. The primary endpoint was 48 h mortality; secondary endpoints included mortality or neurocognitive sequelae at 28 days. Results The trial was stopped early after enrolling 1852/4200 children, including 388 in the severe hypoxaemia stratum (median 7 months; median SpO2 75%) randomised to HFNT (n = 194) or LFO (n = 194) and 1454 in the hypoxaemia stratum (median 9 months; median SpO2 88%) randomised to HFNT (n = 363) vs LFO (n = 364) vs permissive hypoxaemia (n = 727). Per-protocol 15% of patients in the permissive hypoxaemia group received oxygen (when SpO2 |
Databáze: | OpenAIRE |
Externí odkaz: |